Oncolytics Biotech Files June 2024 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, biotech
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH (ONCY) filed its monthly 6-K report on June 20, 2024.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on June 20, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing is for the month of June 2024 and is submitted under the 1934 Securities Exchange Act.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Oncolytics Biotech Inc.'s status as a foreign private issuer.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain new material information that would typically increase risk.
Key Numbers
- 001-38512 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer
- Calgary, Alberta, Canada (location) — Company Headquarters
- 20240620 (date) — Filing Date
FAQ
What type of company is Oncolytics Biotech Inc. according to the filing?
Oncolytics Biotech Inc. is identified as a foreign private issuer in the Pharmaceutical Preparations industry.
When was this Form 6-K filed?
This Form 6-K was filed on June 20, 2024.
Where is Oncolytics Biotech Inc. headquartered?
The company's principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Under which act is this report filed?
This report is filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Does Oncolytics Biotech Inc. file annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under cover of Form 20-F.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-06-20 12:04:42
Filing Documents
- form6kgobletc5fpi.htm (6-K) — 18KB
- gobletc5fpipr.htm (EX-99.1) — 28KB
- 0001129928-24-000046.txt ( ) — 47KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date June 20, 2024 Kirk Look Chief Financial Officer